| Literature DB >> 32566242 |
Haftom Legese1, Hagos Degefa2, Aderajew Gebrewahd1, Haftay Gebremedhin2.
Abstract
BACKGROUND: Isoniazid prophylaxis therapy is a significant public health intervention to prevent the progression of latent tuberculosis to active tuberculosis disease among people living with HIV. Those with HIV are at high risk to develop active Tuberculosis from latent Tuberculosis than those without HIV. Even though there is strong evidence supporting Isoniazid Prophylaxis therapy for Tuberculosis prevention, there is limited information about the implementation of isoniazid prophylaxis therapy in Ethiopia as well as in the study area.Entities:
Keywords: Antiretroviral therapy; Ethiopia; HIV positive; Isoniazid prophylaxis
Year: 2020 PMID: 32566242 PMCID: PMC7301988 DOI: 10.1186/s40794-020-00106-2
Source DB: PubMed Journal: Trop Dis Travel Med Vaccines ISSN: 2055-0936
Socio-demographic characteristics of the study participants in Fre Semaetat primary Hospital Hawzen, Tigrai, Ethiopia from April to August 2019 (N = 372)
| Socio-demographic characteristic’s | Frequency | Percent | |
|---|---|---|---|
| Male | 200 | 53.80 | |
| Female | 172 | 46.20 | |
| 0–14 | 16 | 4.30 | |
| 15–24 | 35 | 9.40 | |
| 25–34 | 69 | 18.50 | |
| > = 35 | 252 | 67.70 | |
| Orthodox | 306 | 82.30 | |
| Muslim | 66 | 17.70 | |
| Protestants | 0 | 0 | |
| Married | 284 | 76.30 | |
| Single | 53 | 14.20 | |
| Divorced | 25 | 6.70 | |
| Widowed | 10 | 2.70 | |
| Cannot read and write | 223 | 59.90 | |
| Primary | 109 | 29.30 | |
| Secondary | 38 | 10.20 | |
| College and above | 2 | 0.50 | |
Baseline clinical characteristics of clients on IPT among HIV positive clients in Fre Semaetat primary Hospital Hawzen, Tigray, Ethiopia from April to August 2019 (N = 372)
| Baseline clinical characteristics | IPT take | Total | |||
|---|---|---|---|---|---|
| Yes | No | ||||
| One | 238(74.1) | 42(82.40) | 280 | 0.002* | |
| Two | 67(20.9%) | 9(17.6%) | 76 | ||
| Three | 3(0.9) | 0(0.0%) | 3 | ||
| Four | 13(4.0) | 0(0.0% | 13 | ||
| < 350 | 94(29.3%) | 14(27.5%) | 108 | 0.010* | |
| 350–499 | 156(48.6%) | 27(152.9%) | 183 | ||
| > = 500 | 71(22.1%) | 10(19.6%) | 81 | ||
| < 18 | 91(28.3%) | 8(15.7%) | 99 | 0.094 | |
| 18–25 | 216(67.3%) | 42(82.4%) | 258 | ||
| > = 25 | 14(4.4%) | 1(2.0%) | 15 | ||
| < 12 mg/dl | 39(12.%) | 0(0.0) | 39 | 0.009* | |
| > = 12 mg/dl | 282(87.9%) | 51(100.0%) | 333 | ||
| < 40 kg | 34(10.6% | 0(0.0) | 34 | 0.000* | |
| 40–49 | 209(65.9%) | 29(56.9%) | 238 | ||
| 50–59 | 56(17.4%) | 21(41.2%) | 77 | ||
| > 60 | 22(6.9%) | 1(2.0%) | 23 | ||
| Good | 200(62.3%) | 34(66.7%) | 234 | 0.020* | |
| Fair | 80(24.9% | 17(33.3%) | 97 | ||
| Poor | 41(12.8%) | 0(0.0) | 41 | ||
Fig. 1Type of ART medication used among HIV positive clients in Fre Semaetat primary Hospital Hospital Hawzen,Tigray, Ethiopia, 2019
Fig. 2Opportunistic infections among HIV positive clients in Fre Semaetat primary Hospital Hospital Hawzen,Tigray, Ethiopia, 2019
Fig. 3IPT utilization among HIV positive clients taking ART medication in Fre Semaetat primary Hospital Hawzien,Tigray, Ethiopia, 2019
Bivariate and multivariable analysis for IPT utilization among HIV positive clients who use ART medication in Fre Semaetat primary Hospital Hawzien, Tigray, Ethiopia from April to August 2019 (N = 372)
| Variables | Category | IPT utilization | COR(95% CI) | AOR(95%CI) | |||
|---|---|---|---|---|---|---|---|
| No | Yes | ||||||
| Male | 40 | 159 | 3.705(1.836,7.478) | 0.000 | 0.034(0.015,0.077) | 0.000* | |
| Female | 11 | 162 | 1 | 1 | |||
| 0–14 | 3 | 13 | 2.402(0.636,9.077) | 0.196 | 0.967(0.147,6.364) | 0.972 | |
| 15–24 | 12 | 23 | 5.431(2.383,12.377) | 0.000 | 2.998(0.676,13.298) | 0.149 | |
| 25–34 | 14 | 55 | 2.650(1.274,5.508) | 0.009 | 2.242(0.950,5.291) | 0.065 | |
| > = 35 | 22 | 230 | 1 | 1 | |||
| Married | 25 | 259 | 0.456(0.267,0.780) | 0.004 | 0.335(0.140,0.806) | 0.016* | |
| Single | 26 | 62 | 1 | 1 | |||
| Yes | 14 | 35 | 1 | 1 | |||
| No | 37 | 286 | 3.092(1.523,6.277) | 0.002 | 0.541(0.214,1.369) | 0.195 | |
| Yes | 14 | 277 | 0.060(0.030,0.120) | 0.000 | 8.693(3.600,20.99) | 0.000* | |
| No | 37 | 44 | 1 | 1 | |||
| Yes | 47 | 243 | 3.772(1.317,10.80) | 0.130 | 3.592(1.162,11.109) | 0.026* | |
| No | 4 | 78 | 1 | 1 | |||
| Yes | 23 | 125 | 0.776 (.482,1.40) | 0.405 | 0.311(0.112,0.868) | 0.026 | |
| No | 28 | 196 | 1 | 1 | |||
| Yes | 24 | 119 | 0.663(0.366,1.20) | .175 | 0.284(0.102,0.790) | 0.016 | |
| No | 27 | 202 | 1 | 1 | |||
| Yes | 14 | 45 | 2.262(1.136,4.509) | 0.020 | 1.487(0.662,3.341) | 0.337 | |
| No | 37 | 276 | 1 | 1 | |||
CI Confidence Interval, COR Crude Odds Ratio, AOR Adjusted Odds Ratio * = p value < 0.05*statistically significant with IPT utilization p ≤ 0.05